Published in Psychopharmacology (Berl) on July 08, 2010
Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov Disord (2012) 1.36
Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors. Eur J Pharmacol (2012) 1.32
α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol Rev (2011) 1.29
Analysis of detailed phenotype profiles reveals CHRNA5-CHRNA3-CHRNB4 gene cluster association with several nicotine dependence traits. Nicotine Tob Res (2012) 1.22
Past major depression and smoking cessation outcome: a systematic review and meta-analysis update. Addiction (2013) 1.12
Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings. Psychopharmacology (Berl) (2011) 0.96
Neuroinflammation, neurodegeneration, and depression. Neurotox Res (2012) 0.95
Smoking cessation and reduction in people with chronic mental illness. BMJ (2015) 0.95
Circuit-wide Transcriptional Profiling Reveals Brain Region-Specific Gene Networks Regulating Depression Susceptibility. Neuron (2016) 0.93
The nicotinic acetylcholine receptor as a target for antidepressant drug development. ScientificWorldJournal (2012) 0.90
Nicotine elicits prolonged calcium signaling along ventral hippocampal axons. PLoS One (2013) 0.90
Clinical features of autoimmune autonomic ganglionopathy and the detection of subunit-specific autoantibodies to the ganglionic acetylcholine receptor in Japanese patients. PLoS One (2015) 0.87
Derivatives of dibenzothiophene for positron emission tomography imaging of α7-nicotinic acetylcholine receptors. J Med Chem (2013) 0.86
Changes in the cholinergic system between bipolar depression and euthymia as measured with [123I]5IA single photon emission computed tomography. Biol Psychiatry (2013) 0.86
Development of [(18)F]ASEM, a specific radiotracer for quantification of the α7-nAChR with positron-emission tomography. Biochem Pharmacol (2015) 0.85
5-(5-(6-[(11)C]methyl-3,6-diazabicyclo[3.2.0]heptan-3-yl)pyridin-2-yl)-1H-indole as a potential PET radioligand for imaging cerebral α7-nAChR in mice. Bioorg Med Chem (2012) 0.85
Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity. J Med Chem (2012) 0.85
Effects of short-term varenicline administration on emotional and cognitive processing in healthy, non-smoking adults: a randomized, double-blind, study. Neuropsychopharmacology (2012) 0.84
Human brain imaging of α7 nAChR with [(18)F]ASEM: a new PET radiotracer for neuropsychiatry and determination of drug occupancy. Mol Imaging Biol (2014) 0.84
Synthesis and evaluation of new radioligands [(11)C]A-833834 and [(11)C]A-752274 for positron-emission tomography of α7-nicotinic acetylcholine receptors. Nucl Med Biol (2013) 0.83
Depression and nicotine dependence from adolescence to young adulthood. Addict Behav (2014) 0.83
Discovery of highly potent and selective α4β2-nicotinic acetylcholine receptor (nAChR) partial agonists containing an isoxazolylpyridine ether scaffold that demonstrate antidepressant-like activity. Part II. J Med Chem (2012) 0.80
Chemistry, pharmacology, and behavioral studies identify chiral cyclopropanes as selective α4β2-nicotinic acetylcholine receptor partial agonists exhibiting an antidepressant profile. Part II. J Med Chem (2013) 0.79
Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats. Psychopharmacology (Berl) (2016) 0.78
Enantiopure Cyclopropane-Bearing Pyridyldiazabicyclo[3.3.0]octanes as Selective α4β2-nAChR Ligands. ACS Med Chem Lett (2014) 0.78
Recent developments in novel antidepressants targeting α4β2-nicotinic acetylcholine receptors. J Med Chem (2014) 0.77
Pharmacokinetics and brain penetration of LF-3-88, (2-[5-[5-(2(S)-azetidinylmethoxyl)-3-pyridyl]-3-isoxazolyl]ethanol), a selective α4β2-nAChR partial agonist and promising antidepressant. J Chromatogr B Analyt Technol Biomed Life Sci (2012) 0.77
The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders:A Potential Noveltreatment? Curr Neuropharmacol (2015) 0.76
Evaluation of the Nicotinic Acetylcholine Receptor-Associated Proteome at Baseline and Following Nicotine Exposure in Human and Mouse Cortex. eNeuro (2016) 0.76
Ethiopathogenesis of depressive disorders. Clin Pract Epidemiol Ment Health (2014) 0.75
Tying up Nicotine: New Selective Competitive Antagonist of the Neuronal Nicotinic Acetylcholine Receptors. ACS Med Chem Lett (2015) 0.75
Neuromodulation, Emotional Feelings and Affective Disorders. Mens Sana Monogr (2016) 0.75
Effects of short-term varenicline administration on cortisol in healthy, non-smoking adults: a randomized, double-blind, study. Psychopharmacology (Berl) (2013) 0.75
Associations of rare nicotinic cholinergic receptor gene variants to nicotine and alcohol dependence. Am J Med Genet B Neuropsychiatr Genet (2016) 0.75
Putative Epigenetic Involvement of the Endocannabinoid System in Anxiety- and Depression-Related Behaviors Caused by Nicotine as a Stressor. PLoS One (2016) 0.75
Cytisine, a Partial Agonist of α4β2 Nicotinic Acetylcholine Receptors, Reduced Unpredictable Chronic Mild Stress-Induced Depression-Like Behaviors. Biomol Ther (Seoul) (2016) 0.75
Effects of tobacco exposure on perinatal suicidal ideation, depression, and anxiety. BMC Public Health (2016) 0.75
Maternal choline status during pregnancy, but not that of betaine, is related to antenatal mental well-being: The growing up in Singapore toward healthy outcomes cohort. Depress Anxiety (2017) 0.75
Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med (2006) 49.95
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science (2003) 16.14
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry (2006) 14.15
Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature (2002) 12.09
The 'Trier Social Stress Test'--a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology (1993) 11.24
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci (2000) 9.12
Depression: a new animal model sensitive to antidepressant treatments. Nature (1977) 8.76
Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry (2009) 8.74
The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) (1985) 7.53
Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev (2009) 5.64
Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res (2002) 4.93
The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry (2007) 4.51
Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ (2009) 4.19
Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci (2006) 4.04
Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict (2005) 3.89
Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit Care Med (2007) 3.63
The HPA axis in major depression: classical theories and new developments. Trends Neurosci (2008) 3.47
Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol (2004) 3.17
It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol (2007) 2.85
Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology (2003) 2.75
Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry (2006) 2.68
Nicotine addiction and comorbidity with alcohol abuse and mental illness. Nat Neurosci (2005) 2.59
Why do we respond so differently? Reviewing determinants of human salivary cortisol responses to challenge. Psychoneuroendocrinology (2008) 2.49
Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction (2007) 2.38
Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry (2008) 2.29
Exacerbation of schizophrenia by varenicline. Am J Psychiatry (2007) 2.27
Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry (2007) 2.06
Nicotinic acetylcholine receptors as targets for antidepressants. Mol Psychiatry (2002) 2.02
Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem (2004) 1.99
A cholinergic-adrenergic hypothesis of mania and depression. Lancet (1972) 1.97
Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol (2004) 1.88
Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. J Pharmacol Exp Ther (2001) 1.74
Phenotypic characterization of an alpha 4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse. J Neurosci (2000) 1.70
Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry (2010) 1.66
Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Saf (2010) 1.64
Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. Neuropharmacology (2007) 1.63
Monoamine oxidase and cigarette smoking. Neurotoxicology (2003) 1.57
High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation. Biol Psychiatry (2004) 1.49
The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta2- or alpha7-nicotinic acetylcholine receptor subunit knockout mice. Psychopharmacology (Berl) (2006) 1.45
Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder: a preliminary study. J Clin Psychopharmacol (2008) 1.41
Acetylcholine and depression. Psychosom Med (1974) 1.41
Corticotropin-releasing factor-1 receptor activation mediates nicotine withdrawal-induced deficit in brain reward function and stress-induced relapse. Biol Psychiatry (2009) 1.38
Nicotine is highly effective at producing desensitization of rat alpha4beta2 neuronal nicotinic receptors. J Physiol (2003) 1.38
Regulation of nicotinic acetylcholine receptor numbers and function by chronic nicotine exposure. Curr Drug Targets CNS Neurol Disord (2002) 1.38
The hypothalamic-pituitary-adrenal (HPA) axis in habitual smokers. Int J Psychophysiol (2005) 1.33
TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity. CNS Neurosci Ther (2008) 1.33
Depression during tobacco abstinence. Nicotine Tob Res (2007) 1.32
The Flinders sensitive line rats: a genetic animal model of depression. Neurosci Biobehav Rev (1993) 1.31
Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology (Berl) (1999) 1.30
Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol (2006) 1.22
Antidepressantlike effects of chronic nicotine on learned helplessness paradigm in rats. Biol Psychiatry (1998) 1.20
Neuro-immune interactions via the cholinergic anti-inflammatory pathway. Life Sci (2007) 1.19
Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect. Eur J Pharmacol (2009) 1.19
Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. J Gen Intern Med (2009) 1.19
Cytisine-based nicotinic partial agonists as novel antidepressant compounds. J Pharmacol Exp Ther (2009) 1.18
Presynaptic nicotinic receptors facilitate monoaminergic transmission. J Neurosci (1998) 1.17
Smoking cessation and depression: current knowledge and future directions. Drug Alcohol Rev (2006) 1.11
Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests. J Psychopharmacol (2008) 1.10
Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. Psychopharmacology (Berl) (2006) 1.10
Varenicline augmentation in depressed smokers: an 8-week, open-label study. J Clin Psychiatry (2009) 1.09
Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry (2009) 1.08
Neurochemical and behavioral effects elicited by bupropion and diethylpropion in rats. Behav Brain Res (2010) 1.06
Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions? Int J Biochem Cell Biol (2009) 1.04
Antidepressant effect of ingested nicotine in female rats of Flinders resistant and sensitive lines. Physiol Behav (1999) 1.04
Neuroendocrine actions of nicotine and of exposure to cigarette smoke: medical implications. Psychoneuroendocrinology (1989) 1.04
Exacerbation of recurrent depression as a result of treatment with varenicline. Am J Psychiatry (2008) 1.03
Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking. Cell Mol Neurobiol (2007) 0.99
Response of the hypothalamo-pituitary-adrenal axis to nicotine. Psychoneuroendocrinology (1998) 0.98
Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine. Depress Anxiety (2002) 0.98
Acetylcholine receptors in dementia and mild cognitive impairment. Eur J Nucl Med Mol Imaging (2008) 0.96
Biological basis for the co-morbidity between smoking and mood disorders. J Dual Diagn (2009) 0.96
Mecamylamine - a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders. Expert Opin Pharmacother (2009) 0.96
Effects of nicotine and mecamylamine on rat dorsal raphe neurons. Eur J Pharmacol (1998) 0.95
Differentiation of the open and closed states of the ionic channels of nicotinic acetylcholine receptors by tricyclic antidepressants. Proc Natl Acad Sci U S A (1981) 0.93
Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction. Curr Opin Investig Drugs (2008) 0.92
Mechanisms of nicotine actions on dorsal raphe serotoninergic neurons. Eur J Pharmacol (2002) 0.91
Nicotine and nicotinic receptor antagonists potentiate the antidepressant-like effects of imipramine and citalopram. Br J Pharmacol (2003) 0.90
Comparison of alterations in c-fos and Egr-1 (zif268) expression throughout the rat brain following acute administration of different classes of antidepressant compounds. Neuropsychopharmacology (2005) 0.90
Antidepressant-like effects of nicotine and mecamylamine in the mouse forced swim and tail suspension tests: role of strain, test and sex. Behav Pharmacol (2009) 0.89
Glutamate-dopamine crosstalk in the rat prefrontal cortex is modulated by Alpha7 nicotinic receptors and potentiated by PNU-120596. J Mol Neurosci (2009) 0.89
Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling; comparison with the hypothalamic response. J Pharmacol Exp Ther (1995) 0.87
Cholinergic modulation of inflammation. Int J Clin Exp Med (2008) 0.87
Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests. Behav Brain Res (2008) 0.87
Chronic desipramine alters stress-induced behaviors and regional expression of the immediate early gene, c-fos. Pharmacol Biochem Behav (1995) 0.85
Antidepressant-like action of nicotine in forced swimming test and brain serotonin in mice. Physiol Behav (2006) 0.85
Interaction between glutamatergic-NMDA and cholinergic-muscarinic systems in classical fear conditioning. Brain Res Bull (2008) 0.85
Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. Expert Opin Pharmacother (2010) 0.84
Sexual diergism in rat hypothalamic-pituitary-adrenal axis responses to cholinergic stimulation and antagonism. Brain Res Bull (2001) 0.82
Relationship between mood improvement and sleep changes with acute nicotine administration in non-smoking major depressed patients. Rev Invest Clin (2002) 0.81
Interaction of selective serotonin reuptake inhibitors with neuronal nicotinic acetylcholine receptors. Biochemistry (2010) 0.80
Stress induces supersensitivity of a cholinergic system in rats. Biol Psychiatry (1986) 0.79
The presence of corticotropin-releasing factor-like immunoreactive synaptic vesicles in axon terminals with nicotinic acetylcholine receptor-like immunoreactivity in the median eminence of the rat. Neurosci Lett (1993) 0.78
Chronic inescapable footshock produces cholinergic system supersensitivity. Biol Psychiatry (1987) 0.76
Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry (2008) 2.86
Decreased adrenocorticotropic hormone and cortisol responses to stress in healthy adults reporting significant childhood maltreatment. Biol Psychiatry (2007) 2.58
Declining use of electroconvulsive therapy in United States general hospitals. Biol Psychiatry (2012) 2.50
Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: effects on hypothalamic-pituitary-adrenal axis reactivity. Biol Psychiatry (2009) 2.44
Childhood maltreatment and telomere shortening: preliminary support for an effect of early stress on cellular aging. Biol Psychiatry (2009) 2.20
A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry (2014) 2.10
Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry (2004) 1.90
Childhood adversity and epigenetic modulation of the leukocyte glucocorticoid receptor: preliminary findings in healthy adults. PLoS One (2012) 1.89
A prospective examination of distress tolerance and early smoking lapse in adult self-quitters. Nicotine Tob Res (2009) 1.87
Childhood parental loss and adult hypothalamic-pituitary-adrenal function. Biol Psychiatry (2008) 1.80
Telomeres and early-life stress: an overview. Biol Psychiatry (2012) 1.75
Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry (2006) 1.70
Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology (2010) 1.56
The current crisis of confidence in antidepressants. J Clin Psychiatry (2011) 1.44
Cerebrospinal fluid corticotropin-releasing factor and perceived early-life stress in depressed patients and healthy control subjects. Neuropsychopharmacology (2004) 1.41
Brain derived neurotrophic factor (BDNF) gene variants and Alzheimer's disease, affective disorders, posttraumatic stress disorder, schizophrenia, and substance dependence. Am J Med Genet B Neuropsychiatr Genet (2006) 1.41
Effect of childhood physical abuse on cortisol stress response. Psychopharmacology (Berl) (2010) 1.34
Effect of childhood emotional abuse and age on cortisol responsivity in adulthood. Biol Psychiatry (2009) 1.30
Gene-environment interactions: early life stress and risk for depressive and anxiety disorders. Psychopharmacology (Berl) (2011) 1.30
Sex differences in emotional and physiological responses to the Trier Social Stress Test. J Behav Ther Exp Psychiatry (2007) 1.24
The role of negative affect in risk for early lapse among low distress tolerance smokers. Addict Behav (2008) 1.23
Genotype-controlled analysis of plasma dopamine beta-hydroxylase activity in psychotic unipolar major depression. Biol Psychiatry (2002) 1.23
Neurosurgery for intractable obsessive-compulsive disorder and depression: critical issues. Neurosurg Clin N Am (2003) 1.20
A functional neuropeptide Y Leu7Pro polymorphism associated with alcohol dependence in a large population sample from the United States. Arch Gen Psychiatry (2002) 1.16
Varenicline augmentation in depressed smokers: an 8-week, open-label study. J Clin Psychiatry (2009) 1.09
Declining use of electroconvulsive therapy in U.S. general hospitals is not restricted to unipolar depression. Biol Psychiatry (2013) 1.08
A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry (2002) 1.08
Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology (2002) 1.08
Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression. Am J Psychiatry (2006) 1.07
The clinical correlates of reported childhood sexual abuse: an association between age at trauma onset and severity of depression and PTSD in adults. J Child Sex Abus (2010) 1.04
Decreased default network connectivity is associated with early life stress in medication-free healthy adults. Eur Neuropsychopharmacol (2012) 1.02
Patterns of quetiapine use in psychiatric inpatients: an examination of off-label use. Ann Clin Psychiatry (2008) 1.01
Development and psychometric evaluation of the Yale-Brown Obsessive-Compulsive Scale--Second Edition. Psychol Assess (2010) 1.01
Update on stress and depression: the role of the hypothalamic-pituitary-adrenal (HPA) axis. Rev Bras Psiquiatr (2004) 0.98
Temperament and hypothalamic-pituitary-adrenal axis function in healthy adults. Psychoneuroendocrinology (2006) 0.97
Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects. Brain Stimul (2012) 0.95
The relationship between childhood abuse and adult personality disorder symptoms. J Pers Disord (2007) 0.94
Childhood parental loss and adult psychopathology: effects of loss characteristics and contextual factors. Int J Psychiatry Med (2008) 0.93
Cortisol and ACTH responses to the Dex/CRH test: influence of temperament. Horm Behav (2008) 0.93
Increased cerebrospinal fluid corticotropin-releasing factor concentrations during tryptophan depletion in healthy adults. Biol Psychiatry (2004) 0.90
Telomeres, early-life stress and mental illness. Adv Psychosom Med (2015) 0.90
The nicotinic acetylcholine receptor as a target for antidepressant drug development. ScientificWorldJournal (2012) 0.90
A retrospective follow-up study of body dysmorphic disorder. Compr Psychiatry (2005) 0.90
Sex differences in the use of coping strategies: predictors of anxiety and depressive symptoms. Depress Anxiety (2008) 0.89
Crisis of confidence: antidepressant risk versus benefit. J Clin Psychiatry (2011) 0.89
Trends in psychotropic drug use in a child psychiatric hospital from 1991-1998. J Child Adolesc Psychopharmacol (2004) 0.89
Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. J Affect Disord (2004) 0.88
Childhood maltreatment and adult personality disorder symptoms: influence of maltreatment type. Psychiatry Res (2009) 0.86
A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period. J Clin Psychiatry (2014) 0.86
Interplay between childhood maltreatment, parental bonding, and gender effects: impact on quality of life. Child Abuse Negl (2007) 0.86
Regional homogeneity and resting state functional connectivity: associations with exposure to early life stress. Psychiatry Res (2013) 0.85
Augmentation of antidepressants with atypical antipsychotics: a review of the current literature. J Psychiatr Pract (2008) 0.85